Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

Novartis and Bristol Myers Squibb have paused several CAR-T cell therapy trials in autoimmune diseases due to immune-related adverse events, prompting safety reviews of their rapid manufacturing platform therapies targeting CD19.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 31 Aug 2026 and 2 Sep 2026.

◆ ◆ The Wire takeaway

You face a sudden pause in autoimmune CAR-T trials targeting CD19 due to safety concerns around rapid manufacturing. This forces a rethink on trial risk management and heightens scrutiny on new cell therapies in autoimmune diseases.

◆ Coverage

2 sources · first reported 31 Aug 2026 · latest 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechcar-tautoimmuneclinical-trialssafety-eventsbioscienceregulatory-pause